Alternate-Day Buprenorphine. Phase V - 6
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000224
Collaborator
University of Vermont (Other)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate buprenorphine blockade challenge.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Study Type:
Interventional
Intervention Model:
Crossover Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Alternate-Day Buprenorphine. Phase V
Study Start Date
:
Feb 1, 1993
Outcome Measures
Primary Outcome Measures
- Drug use []
- Opioid withdrawal []
- Subjective dose estimate []
- Drug effect characteristics: ARCI []
- Physiological changes in: pupil diameter []
- Physiological changes in: blood pressure []
- Physiological changes in: heart rate []
- Physiological changes in: respiration []
- Physiological changes in: bup plasma levels []
Eligibility Criteria
Criteria
Ages Eligible for Study:
30 Years
to 49 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Treatment Research Center | Burlington | Vermont | United States | 05401 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- University of Vermont
Investigators
- Principal Investigator: Warren Bickel, Ph.D., University of Vermont
Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000224
Other Study ID Numbers:
- NIDA-06969-6
- R01-06969-6
First Posted:
Sep 21, 1999
Last Update Posted:
Jun 24, 2005
Last Verified:
Apr 1, 1996